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Synthetic inhibitors of trypsin-like serine proteases were covalently immobilized to polymeric
materials to passivate coagulation enzymes during blood contact. The inhibitory potency of a
structurally simple and larger, more complex amidine derivatives was assessed against thrombin and
factor Xa. After adsorption of serum albumin, the polymer ﬁlms decorated with either one of the
inhibitors were found to scavenge thrombin—with a higher afﬁnity in the case of the larger
inhibitor—but not factor Xa. Both inhibitor-containing coatings showed a signiﬁcantly reduced
thrombogenicity, coagulation activation, as well as complement activation when incubated with
freshly drawn human whole blood in vitro. The authors conclude that the introduced principle offers
a promising approach for hemocompatible materials for short term applications. Even rather simple
inhibitors can be successfully employed for that purpose. © 2006 American Vacuum Society.
DOI: 10.1116/1.2431753
I. INTRODUCTION
The application of blood-contacting medical devices often
is limited by the activation of hemostatic mechanisms which
are physiologically directed towards the prevention of blood
loss from injured blood vessels.1 One major consequence of
the exposure of blood to almost any foreign material—as
well as air—is the activation of thrombin and factor Xa
FXa, two key enzymes of the blood coagulation cascade.
Thrombin, which is formed after the catalytic cleavage of its
plasma precursor, prothrombin factor II, through the tenase
factor FXa+FVa+Ca2++phospholipid converts ﬁbrinogen
into ﬁbrin. Additionally it stimulates platelets with respect to
expansion, aggregation, and release of components of the
alpha and dense granules. Therefore, blood cell aggregates
thrombi are formed on materials surfaces and microemboli
aggregate portions might be liberated into the blood stream.
The clots can induce a dysfunction of the medical devices,
while the microemboli create the risk of harming the func-
tion of vital organs. The expressions of the bioincompatibil-
ity are variable and numerous: embolic complications with
catheters,2 thrombotic complications associated with a car-
diovascular bypass,3 or occlusion of stents.4
To prevent these undesired blood responses, several strat-
egies rely on the regulation of blood coagulation enzymes or
passivation of the material surface. Enzyme activities might
be turned off by loading biologically active substances into a
polymer matrix or bonding them to the material surface.
Commonly, these coatings are based on natural substances of
mammalian origin: immobilization5–7 or release8 of antico-
agulant sulfated polysaccharides mainly heparin or coat-
ings based on anticoagulant proteins as thrombomodulin.9
Beyond that hirudin,10,11 a nonmammalian protein preventing
blood clotting was utilized to inhibit the functions of throm-
bin. Coatings with low thrombogenicity were also prepared
by sustained release of a synthetic thrombin inhibitor from
synthetic polymer matrices12 and by covalent immobilization
of a nonsteroidal anti-inﬂammatory drug,13 inhibitors of
platelet activation, and aggregation14 or thrombin.15,16 On the
other hand, materials passivated with polyethylene glycol
molecules were reported as blood compatible cushions by
minimizing and retarding the adsorption of plasma proteins
as well as limiting the platelet adhesion.17–19 Other protein
resistant surfaces relied on the surface decoration with
phosphorylcholine.20 Protein adsorption on both surfaces
was essentially the same for similar chain length and
density.21
While all of the above-listed principles were demon-
strated to be successful in appropriate settings as the com-
monly used systemic application of heparin, their utilization
in order to gain hemocompatible medical devices remained
so far rather limited. This limited translation of the previ-
ously developed strategies into practice provokes research
towards more simple, deﬁned, and robust anticoagulant
coatings.
To address this challenge, we focus on the use of synthetic
amidine derivatives described in literature as direct inhibitors
of trypsin-like serine proteases i.e., blood coagulation en-
zymes such as thrombin or factor Xa but similarly of en-
zymes involved in the inﬂammation process such as comple-
ment C 1s.22 We already demonstrated that the covalent
grafting of an amidine-containing inhibitor through reactive
polymer ﬁlms provides promising short term blood compat-
ibility to the modiﬁed materials in vitro.23 Optimization of
the structure of the inhibitor, its linkage to the carrier mate-
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rial, and the overall physicochemical characteristics of the
functionalized layer are assumed to allow further enhance-
ment of the anticoagulant performance of the coatings.
In that context, the present study concerns the preparation
and surface characterization of polymer coatings containing
two different amidine-based molecules. Analyzing physico-
chemical characteristics of the inhibitor-decorated surfaces,
their interactions with trypsin-like serine proteases in solu-
tion, and the biological response after contact with human
whole blood, we show that the performance of amidine-
based anticoagulant coatings is mainly controlled by the in-
hibitor structure.
II. MATERIALS AND METHODS
A. Amidine derivatives
4-aminobenzamidine dihydrochloride or inhibitor 1 was
purchased from Aldrich-Fluka Chemicals Deisenhofen,
Germany and used without further puriﬁcation.
N-2-naphthalenesulfonyl-L-lysyl-4-amidino-DL-phenylal-
aninepiperidide ditriﬂuoroacetate or inhibitor 2 was synthe-
sized with slight modiﬁcations of a published route.24 The
structure of the inhibitor 2 was conﬁrmed by NMR 1H and
13C and mass spectroscopy MALDI-TOF data not
shown.
B. Details of the computational procedure
We applied the PM3 Hamiltonian,25 in the form of the
software package SPARTAN26 using the WINDOWS2000 plat-
form. The structures of the inhibitor molecules 1 and 2 were
generated by the molecule editor and the energy was mini-
mized without any constraints.
Thrombin is composed of two polypeptide chains A and B
that are covalently linked through a disulﬁde bridge.27 The B
chain has the typical folded form of serine proteases28 and
involves the functional epitopes of the enzyme in a deep
canyonlike binding site pocket on its molecular surface. In
order to perform computational calculations it is necessary to
restrict the large thrombin molecule. We focused on the rel-
evant amino acid residues of the binding site pocket. There-
fore, the atom coordinates of the thrombin binding site resi-
dues for the modeling studies were extracted from x-ray
structure data of human -thrombin from the Brookhaven
Protein Data Bank.29 The truncation points of residues were
saturated with hydrogen.
For the semiempirical calculations the inhibitor moieties
were placed into the binding site of thrombin and the energy
of the complex was minimized, whereas the residues forming
the thrombin active site were kept ﬁxed. The binding
strength of inhibitor-thrombin complexes H was
calculated.
C. Determination of the inhibitor potential
The inhibition of human thrombin and factor Xa was de-
termined in 96 well plates using a chromogenic enzyme ac-
tivity assay. All assays were carried out in a total volume of
200 l. Inhibitor dilutions 50 l were incubated 5 min at
25 °C in 0.05 M tris buffer Sigma-Aldrich Chemie GmbH,
Steinheim, Germany pH 7.4, containing 10% DMSO, 0.1M
NaCl, and 1 mg/ml bovine serum albumin BSA Sigma-
Aldrich Chemie GmbH, Steinheim, Germany with 100 l
chromogenic substrate. The reactions were started with the
addition of thrombin or factor Xa. The enzyme activities
were evaluated from the hydrolysis rate of the substrates
measured at 405 nm using a Genios spectrophotometer
Tecan, Austria GmbH, Grödig/Salzburg, Austria. The ki-
netic assays were performed over 20 min, in duplicate at
three different inhibitor and six different substrate concentra-
tions. The inhibition constant values Ki were determined
using a direct Michaelis-Menten analysis. The calibration for
the reaction product para-nitroaniline pNA Sigma-Aldrich
Chemie GmbH, Steinheim, Germany was done using con-
centrations ranging from 0 to 200 M.
Enzyme and chromogenic substrate concentrations and
supplier for each assay were as follows: human thrombin
T-6884, Sigma-Aldrich Chemie GmbH, Steinheim, Ger-
many, at ﬁnal concentration of 1.5 nM; thrombin-substrate
H-D-Phe-Pip-Arg-pNA, 2HCl, or S-2238 Chromogenix, Mi-
lano, Italy at ﬁnal concentrations between 0 and 300 M;
factor Xa Haemochrom Diagnostica GmbH, Essen, Ger-
many at ﬁnal concentration of 0.7 nM; and FXa-substrate
Z-D-Arg-Gly-Arg-pNA or S-2765 Haemochrom Diagnos-
tica GmbH, Essen, Germany at ﬁnal concentrations com-
prised ranging from 0 to 400 M.
D. Surface modiﬁcation/inhibitor immobilization
Polypropylene-alt-maleic anhydride copolymer or
PP-MA MW=39 000, Leuna-Werke AG, Germany was
precipitated from tetrahydrofuran Fluka, Deisenhofen, Ger-
many with hexane Fluka, ﬁltered out and thereafter inten-
sively washed with hexane to remove oleﬁn impurities. The
reannelation of the anhydride moieties was completed at
120 °C for 20 h. Stable thin ﬁlms of PP-MA were prepared
by spin-coating a 0.1% copolymer solution in 2-butanone
onto cleaned and amino-silanized silicon wafers or glass
cover slips prepared according to the procedure described
elsewhere.30
The references utilized in this study were PP-MA ﬁlms:
ﬁrst, the polymer ﬁlms were freshly annealed 120 °C, 2 h
shortly before the experiment PP-MAanh and, second, a to-
tal hydrolysis of the anhydride moieties of the copolymer
ﬁlm was achieved by autoclaving 120 °C, saturated water
vapor, 20 min, autoclave: 2540 EL, Systec, Wettenberg, Ger-
many and led to a negatively charged surface PP-MAhyd.
The immobilization of the inhibitors 1 and 2 was accom-
plished by direct modiﬁcation of nonhydrolyzed thin ﬁlms of
PP-MAanh: the copolymer ﬁlms were immersed overnight in
a 5 mM solution of the inhibitor in 0.1M borate buffer pH
=8 containing 10% DMSO, subsequently rinsed with deion-
ized water and 0.01N HCl solution, and annealed 2 h at
120 °C leading to the formation of the surfaces PP-MA-1
and PP-MA-2, respectively.
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E. Physicochemical characterization
Layer thickness values were determined by ellipsometry
using a single-wavelength device 632 nm EL X-02C DER
Riss Ellipsometerbau GbmH, Ratzeburg, Germany. Coat-
ings were performed in duplicate. The mean thickness of
PP-MA ﬁlms and modiﬁcations was determined from at least
three measurements each and estimated using an optical 4
four-layers model Si/SiO2/polymer/ambient.31 The optical
constants of Si 3.8705− j0.0168 and SiO2 1.4571
+ j0.0000 layers were taken from literature.32 More details
of the method and the analysis are given in Ref. 33. The
refractive indices of the polyalkene-alt-maleic anhydride
thin ﬁlms were determined to be 1.5037+ j0.0000 by means
of spectroscopic ellipsometry and kept invariant for the
evaluation of the ellipsometry data of the modiﬁed layers.
The given thickness values represent only the approximate
change in ﬁlm thickness since the intrinsic refractive indices
of benzamidine-type inhibitors have not been determined
yet.
Dynamic water contact angle measurements were carried
out on an optical contact angle device OCA 30 Dataphysics,
Filderstadt, Germany. Droplets of Millipore water were, re-
spectively, expanded and reduced with a velocity of
0.5 l s−1 to obtain advancing and receding contact angles.
The values are reported as average of three measurements.
X-ray photoelectron spectroscopy XPS was carried out
using an Amicus spectrometer Kratos Analytical, UK
equipped with a nonmonochromatic Mg K x-ray source op-
erated at 12 kV and 240 W. The kinetic energy of photoelec-
trons was determined using an analyzer with a pass energy of
75 eV. The take-off angle, deﬁned as the angle between
sample surface normal and the electron optical axis of the
spectrometer, was 0°. Spectra were referenced to the hydro-
carbon C 1s peak at a binding energy of 285.00 eV. Quanti-
tative elemental compositions were determined from the
peak areas of the high resolution spectra C 1s, N 1s, O 1s,
S 2p, and Si 2p using experimentally determined sensitivity
factors and the spectrometer transmission function. The sur-
face density of the inhibitors 1 and 2 was estimated from the
elemental composition by a linear equation analysis assum-
ing a density of 2.85 g cm−3 of the detected SiO2 from the
silicon wafer substrate and a mean attenuation length of the
XPS signal in the substrate and the surface layer of about
3 nm.34,35 Within this routine the elemental compositions C,
N, S, and Si of the layer components SiO2, PP-MA, PP-
MA-1, or PP-MA-2 were ﬁtted to the XPS data in a least
square sense.
F. Serum albumin adsorption
Fluorescent labeled bovine serum albumin BSA-TRITC
tetramethylrhodamine isothiocyanate was used as commer-
cially available Rockland, Gilbertsville, PA. Unlabeled
BSA was purchased from Sigma Sigma-Aldrich Chemie
GmbH, Steinheim, Germany. For protein adsorption experi-
ments, the polymer surfaces were immersed in a solution of




4 nonlabeled protein in phosphate buffered sa-
line PBS Sigma-Aldrich Chemie GmbH, Steinheim, Ger-
many at pH 7.4 for 2 h. Fluorescence confocal laser scan-
ning microscopy TCS SP, Leica, Bensheim, Germany was
performed to reveal information from the plane of adsorption
directly on the substrate surface. The experiments have been
repeated twice. Laser intensities were calibrated prior to each
measurement by using the InSpeck Orange calibration kit
Molecular Probes. The amount of immobilized serum albu-
min on the copolymer surfaces PP-MAanh and PP-MAhyd was
quantiﬁed by HPLC-based amino acid analysis of the protein
mixtures as described elsewhere.36
G. Thrombin and factor Xa binding studies
The amounts of thrombin and factor Xa remaining in so-
lution after contact with the modiﬁed surfaces were assayed
using the chromogenic substrates S-2238 and S-2765, re-
spectively. The reference surfaces PP-MAanh and PP-MAhyd
and the test surfaces PP-MA-1 and PP-MA-2 were placed
ﬂat into customized screening chambers having a test-
material area of 2 cm2. The tested surfaces were incubated
for 15 min with 200 l PBS pH 7.4 containing 10 mg/ml
BSA and 0.1M NaCl. After incubation, the buffer solution
was removed; thrombin 200 l; 60 nmol l−1 or factor Xa in
PBS 200 l; 60 nmol l−1 in Tris buffer pH 7.4, Sigma-
Aldrich Chemie GmbH, Steinheim, Germany were then
added and equilibrated under agitation for 30 min at 25 °C.
Then the supernatant solution was removed and diluted by a
factor of 40 using tris buffer. 75 l of this solution were
incubated with chromogenic substrates 250 M, 75 l in
the wells of a 96-well microtiter plate for 60 min at 25 °C.
The residual enzymatic activities were evaluated by measur-
ing the amount of released p-nitroaniline at 405 nm at a re-
action time t=25 min. The assays were performed twice,
each time on ﬁve or six similar samples in parallel and re-
ported normalized to the nonhydrolyzed PP-MA ﬁlms
PP-MAanh.
The relative amounts of adsorbed enzyme on the surfaces
were detected by immunostaining-ﬂuorescence spectroscopy.
After removal of the solution containing thrombin, the
samples were rinsed three times with PBS. Afterwards, the
samples were incubated for 1 h with a monoclonal anti-
thrombin antibody 50 g ml−1, Acris, Bad Nauheim, Ger-
many followed by extensive rinsing three times with PBS.
Thereafter, a TRITC labeled secondary antibody 1:50, don-
key antisheep, Dianova, Hamburg, Germany was incubated
for 30 min. The surfaces were imaged using a confocal laser
scanning microscope having a 40 oil immersion objective.
The similar procedure was applied for the detection of ad-
sorbed factor Xa using a primary mouse antihuman factor X
IgG American Diagnostica GmbH, Pfungstadt, Germany
and a TRITC labeled secondary antibody 1:50, donkey an-
tigoat IgG, Dianova, Hamburg, Germany.
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H. In vitro hemocompatibility assays
The generated materials were incubated with freshly
drawn human blood. Brieﬂy, whole human blood 60 ml
was drawn by venopuncture with a 19 gauge needle into two
medical syringes Braun, Melsungen, Germany from a male
healthy donor who did not take any medication for more than
10 days. Anticoagulation was achieved with heparin sodium
salt grade 1-a 2 IU/ml H-3149 Sigma-Aldrich Chemie
GmbH, Steinheim, Germany. The study was approved by
the Ethics Committee of the Dresden University Hospital,
Dresden, Germany. Informed consent was obtained from the
donor before blood drawing. The assays were performed in
duplicate, each time any marker being tested from three dif-
ferent samples. The blood was ﬁlled into the in-house built
incubation chambers Fig. 1 directly from the syringes. In-
cubation chambers modiﬁed after Ref. 37 with a test-material
area of 6.3 cm2, were ﬁlled with approximately 2 ml of
blood avoiding the formation of air bubbles.
To reduce the sedimentation of blood cells during the in-
cubation phase 2 h, the chambers were turned slowly by a
rotary construction with an epicyclic gear which was placed
in an incubator B6030, Heraeus, Hanau, Germany at
37 °C. Commercial enzyme-linked immunosorbent assays
ELISAs were used to characterize the changes in activation
markers for coagulation thrombin-antithrombin complex,
TAT, complement activation complement fragment C5a,
and thrombogenicity platelet factor 4, PF4. ELISAs, used
to quantify the latter substances, were purchased as follows:
TAT Enzygnost®TAT micro, DADE Behring Marburg, Ger-
many, Zymutest PF4 HYPHEN BioMed, Neuville sur
Oise, France, and C5a C5a-Micro DRG Diagnostica, Mar-
burg, Germany. The ELISA plates were analyzed using an
anthos 2010 photometer Anthos Mikrosystems, Krefeld,
Germany. Cell numbers leukocytes, platelets, and erythro-
cytes were analyzed by means of a blood analyzer Coulter
AcTdiff, Krefeld, Germany. The results are presented as the
mean and standard deviation SD.
I. Surface analysis of complement activation
The surfaces were rinsed carefully with veronal-buffered
saline Institut Virion, Rüschlikon/Zürich, Switzerland.
Then, they were rinsed with distilled water to remove adher-
ent salt and frozen at −70 °C until analysis. We used PBS
containing 1% BSA and 0.1% Tween20 as working buffer
and PBS containing 0.1% Tween 20 as washing buffer. Be-
fore analysis the surfaces were incubated with working
buffer for 15 min. Then the samples were incubated for
30 min with an antibody to C5b-9 DAKO, Glostrup, Den-
mark followed by a secondary antibody DakoCytomatik,
Hamburg, Germany labeled with horse radish peroxidase.
To quantify the bound antibody using a colorimetic reaction,
the surfaces were incubated, after washing, for 20 min in the
presence of 1,2-ortho-phenylendiamine dihydrochloride
Sigma-Aldrich Chemie GmbH, Steinheim, Germany. The
reaction was stopped with 3M HCl and the adsorption read at
450 nm.
III. RESULTS AND DISCUSSION
Synthetic derivatives of benzamidine are described in the
literature as direct inhibitors of trypsin-like serine proteases.
Both the central enzymes of the blood coagulation cascade,
thrombin and factor Xa, are sharing trypsin’s preference for
the binding of basic amino acid residues with Asp 189
present at the base of the primary speciﬁcity S1 pocket of
the enzyme. Due to their basic character, benzamidine
pKa=11.638 and its derivatives are ligand arginine-
mimicking molecules: the decoy molecules can bind the pro-
tease active center instead of its natural substrates.
One example of such a structure is the thrombin inhibitor
N--naphthylsulfonylglycyl-4-amidinophenyl-alanine pi-
peridide NAPAP which is a result of extensive structure-
activity relationship studies on piperidine amide derivatives
of N-arylsulfonyl benzamidine.39
The structure of the two molecules, a small benzamidine
derivative and a NAPAP analog, used for this study are dis-
played in Fig. 2. A structural prerequisite of the studied
arginine-mimicking molecules is the presence of the primary
amino group allowing for an effective attachment of the ac-
tive compounds onto the reactive polymeric carrier. We
worked with the commercial p-amino benzamidine inibitor
1, well known for its inhibitory activity of different serine
proteases,16 and the inhibitor 2 in which the glycine of
NAPAP was replaced by a lysine residue. Semiempirically
calculated orientations of the molecules 1 and 2 to amino
acid residues of the active site of thrombin are shown in
Fig. 3.
The calculated orientations of inhibitors 1 and 2 in the
thrombin binding site are in very good agreement with the
experimental x-ray values of thrombin complexes with
4-aminobenzamidine40 and NAPAP,41 respectively. The posi-
FIG. 1. Screening chamber for in vitro hemocompatibility assays. Test-
material area 6.3 cm2; blood volume ﬁlled in: approximately 2 ml.
FIG. 2. Structure of the benzamidine-type inhibitors.
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tively charged benzamidine group of the inhibitors interacts
with the acidic carboxylate group of the amino acid
Asp18942 at the base of the catalytic pocket S1 and forms the
typical ionic pair. The distances between the side chain of
Asp189 and the benzamidine group of inhibitors 1 and 2 are
1.72 Å. In comparison to the small inhibitor 1 the branched
inhibitor 2 completely ﬁlls the hydrophobic pockets S2 and
S3 of the thrombin binding site. The length of the lysine
residue of the inhibitor 2 is 5.6 Å, and it sticks out of the
thrombin binding site.
The theoretically estimated differences in complex bind-
ing enthalpies H are summarized in Table I. The
thrombin-inhibitor complex structures are lower in energy
than that of the separate molecules. The energetic stabiliza-
tion of the inhibitor-thrombin complex results from favorable
effects and interactions, e.g., hydrogen bonds, between the
inhibitor molecules and the enzyme binding site.
The ability of these derivatives to inhibit thrombin and
factor Xa in solution was measured using chromogenic sub-
strate assays. The inhibition constants Ki are also summa-
rized in Table I.
The experimental data showed that, in solution, the syn-
thesized compounds are effective inhibitors of thrombin as
well as of factor Xa. However, the p-aminobenzamidine in-
hibitor 1 demonstrated a selectivity index SI factor Xa/
thrombin of 0.06 while, as expected from modeling and lit-
erature data, the derivative 2 was highly selective against
thrombin SI=1025. The different SIs are easily explained
by the structural differences existing between the active cen-
ters of the two enzymes: although strong similarities of the
S1 speciﬁcity pockets in which the amidine binding occurs
of the two enzymes exist, other subsites are showing distinct
topologies. As an example, the hydrophobic subsite S2 in
thrombin is smaller and only solvent accessible in factor Xa
forcing benzamidine-based inhibitors to utilize two different
conformations for the interaction with thrombin and factor
Xa.43 In our case, the hydrophobic naphthyl and piperidine
substituents of 2 when stabilizing the thrombin-inhibitor 2
complex disadvantage the interactions with factor Xa.
A schematic representation of planar thin ﬁlms of deriva-
tized polypropylene-alt-maleic anhydride copolymers co-
valently attached to a solid support silicon and glass cover-
slips is displayed in Fig. 4 bottom. Previous studies on the
swelling behavior of such substrates before modiﬁcation
i.e., bearing anhydride groups revealed the formation of
brush-like polymer layers resulting in a three-dimensional
presentation of the reactive groups in the ﬁlms Fig. 4
top.44 The principle of the surface immobilization of the
synthetic inhibitor molecules is based on a nucleophilic re-
action between the amino group present in the inhibitor and
free surface anhydride groups of the polymer layer45 gener-
ating a covalent link between the active moieties and the
polymer surface. Inhibitor-modiﬁed surfaces were prepared
with both inhibitors leading to the formation of PP-MA-1
and PP-MA-2. The reference substrates were annealed or
hydrolyzed nonmodiﬁed polymer ﬁlms reported as PP-
MAanh and PP-MAhyd, respectively.
FIG. 3. Scheme of binding site orientation of the derivatives 1 left and 2
right to amino acid residues in thrombin active site.
TABLE I. Calculated heat of formation PM3 of inhibitors, thrombin binding
site residues, and inhibitor-thrombin complexes as well as inhibition con-
stants against thrombin and factor Xa as determined by chromogenic assays.
1 2 Thrombin




Thrombin: Ki M 422±54 0.08±0.03 ¯
Factor Xa: Ki M 26±10 82±28 ¯
FIG. 4. Schemes of the inhibitor-modiﬁed polymer ﬁlms where R represents
one of the benzamidine—based inhibitors 1 and 2.
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The substrate modiﬁcations were characterized with re-
spect to changes in ﬁlm thickness values, atomic composi-
tion of the polymer ﬁlms both listed in Table II, as well as
surface wettability reported in Table III. Analysis of the
inhibitor treated surfaces demonstrated that a surface modi-
ﬁcation had occurred. The increase of the layer thickness
values compared to the control indicated the attachment of
the benzamidine-containing molecules.
Based on the elemental composition determined by x-ray
photoelectron spectroscopy Table II, the surface density of
the immobilized molecules 1 and 2 was estimated as brieﬂy
outlined in Sec. II. For PP-MA-1 a lower surface density of
61013 cm−2 was found in comparison to a higher surface
density of 21014 cm−2 for PP-MA-2.
A prepassivation of the surfaces with serum albumin can
be considered as a model of the primary plasma protein ad-
sorption phenomenon i.e., the protein layer covering any
material surface within seconds after contact with body ﬂuid
blood/plasma/serum.1 The serum albumin adsorption data,
at the chosen solution concentration of 250 g ml−1 after 2 h
of adsorption, are depicted in Fig. 5. HPLC-based amino
acid analysis studies28 which were made on the adsorption of
serum albumin from a 250 g ml−1 concentrated buffer so-
lution onto the references PP-MAanh and PP-MAhyd substrate
quantiﬁed the surface coverage of those surfaces by serum
albumin at 0.32±0.11 and 0.18±0.01 g cm−2, respectively.
A hypothetical monolayer of albumin molecules was calcu-
lated to be 0.24 g cm−2.46
Previous work demonstrated the effective tethering of
proteins onto annealed maleic anhydride copolymer ﬁlms
through formation of an amide linkage between the surface
anhydride groups and the -lysine side chains of the
protein.47–49 The incubation of PP-MAanh in the presence of
serum albumin as also resulted in surface passivation due to
the protein covalent attachment.
On the inhibitor-decorated surfaces PP-MA-1 and PP-
MA-2 the surface coverage by albumin is comparable to the
situation on PP-MAhyd. The surface coverage is reduced by a
factor 1.5 compared to PP-MAanh.
The interactions of the blood coagulation enzymes
thrombin and factor Xa with modiﬁed and nonmodiﬁed
PP-MA substrates were characterized by determining the en-
zymatic activities of thrombin and factor Xa in solution after
contact with the tested surfaces previously incubated in the
presence of a serum albumin solution. In parallel the amount
of adsorbed proteins was qualitatively evaluated by
immunostaining/ﬂuorescence spectroscopy. The collected
data are shown in Figs. 6 and 7, respectively.
The lowest thrombin adsorption was observed on PP-
MAanh due to the covalent attachment of serum albumin and
the resulting passivation of the surface. An enhanced throm-
bin adsorption was observed on PP-MAhyd. In that case the
blood coagulation enzyme was able to displace albumin and
interact with the surface. The amount of adsorbed thrombin
was increased when the inhibitor molecules were immobi-
lized at the material surface suggesting that benzamidine-
modiﬁed surfaces were able to adsorb thrombin with high
afﬁnity. Yet, a further increase of the antithrombin inhibitory
strength of the immobilized molecule PP-MA-2 versus PP-
MA-1 manifests itself in the thrombin afﬁnity of the surface
reduction of thrombin activity in solution Fig. 6 left
associated with an enhancement of enzyme adsorption at the
material surface Fig. 7.
Unlike thrombin, as seen in Fig. 6 right as well as in
confocal laser scanning microscopy images data not
shown, no evidence of a binding of factor Xa onto the tested
surfaces could be seen: we hypothesized that factor Xa was
TABLE II. Change in ﬁlm thickness values and atomic composition of inhibitor-modiﬁed PP-MA layers as
determined by ellipsometry and XPS at. %. The results are reported referenced to PP-MAanh.
Film thickness nm C 1s % O 1s % N 1s % Si 2p % S 2p %
PP-MAanh 3.1±0.4 53.4 32.7 0.5 13.4 0
PP-MA-1 +0.4±0.1 −2.7 −0.1 +1.9 +0.9 0
PP-MA-2 +2.4±0.4 +13.8 −11.4 +5.3 −8.2 +0.5
TABLE III. Surface wettabilities. P=PTFE, G=glass.
Pa Ga PP-MAhyd PP-MA-1 PP-MA-2
Advancing ° 102 28 43±2 71±1 71±1
Receding ° 88 35 31±1 42±1 40±1
aReference 29.
FIG. 5. Adsorbed serum albumin on modiﬁed and nonmodiﬁed substrates as
determined by laser scanning microscopy.
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not able to displace the preadsorbed albumin layer. An im-
provement of the hemocompatibility characteristics of these
surfaces due to a factor Xa scavenging and inhibition could
be ruled out.
To study the interaction of blood proteins and cells with
the nonmodiﬁed materials PP-MAhyd and inhibitor-
containing substrates, PP-MA-1 and -2, we investigated the
changes in different activation markers, such as the blood
cell number, activation of the coagulation cascade, comple-
ment system, and thrombocytes using dedicated incubation
experiments with freshly drawn human whole blood. The
customized incubation system is depicted in Fig. 1. The ma-
terials were compared using ELISAs for the following pa-
rameters: formation of the thrombin-antithrombin complex
for coagulation activation Fig. 8 and release of PF4 from
the -granula one of the several platelet reactions after ac-
tivation Fig. 9. Additionally, the number of thrombocytes
in blood is compared between the samples in Table IV. The
generated surfaces are referenced to A which is the value of
the corresponding marker in human whole blood before in-
cubation. A reference material P, polytetraﬂuoroethylene
PTFE, which is extensively used in medical devices more
than 80% of vascular accesses in the United States being
FIG. 6. Remaining enzyme activities in solution after contact with the
inhibitor-modiﬁed and nonmodiﬁed PP-MA ﬁlms: thrombin top and factor
Xa bottom. The results are reported referenced to PP-MAanh. Each assay
represents the average value of at least four single measurements.
FIG. 7. Adsorption of thrombin on modiﬁed and nonmodiﬁed surface
PP-MA substrates as determined by laser scanning microscopy.
FIG. 8. Concentrations of TAT in blood plasma before A and after blood
incubation with samples for 2 h. Reference materials: P=PTFE and G
=glass. The error bars are standard deviations n=6.
FIG. 9. Concentrations of PF4 in blood plasma before A and after blood
incubation with samples for 2 h. Reference materials: P=PTFE and G
=glass. The error bars are standard deviations n=6.
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expanded PTFE grafts was included in the assay. Glass G
was also chosen as reference due to its high procoagulant
activity.
A strong formation of TAT was shown by PP-MAhyd and
glass. Being less hydrophilic than glass as assessed by the
surface wettability data depicted in Table III, PP-MAhyd
nevertheless exhibits a high density of negatively charged
groups 11014 acid groups/cm2.25 Negatively charged
surfaces are known to initiate the contact activation of the
blood coagulation system.50 The drop in platelet number
from the initial value of 207±5109 to 165±16 and
169±21109 after the incubation with glass and PP-
MAhyd, respectively, conﬁrms the fact that both are highly
activating surfaces.
PP-MA-1 and PP-MA-2 surfaces displayed a signiﬁcant
decrease of the thrombocyte PF4 and coagulation TAT
activation markers compared to the nonmodiﬁed PP-MAhyd:
The immobilization of the two benzamidine-based inhibitors
resulted in an observable decrease of the activation of the
cascade systems. Yet, the slight differences between the two
could not be considered as signiﬁcant. The inhibitory
strength determined in solution of the attached molecules,
even if inﬂuencing the amount of scavenged thrombin as
proved by the thrombin adsorption experiments Figs. 5 and
6, cannot be considered as governing the compatibility of
the surface with whole blood: the capability of PP-MA-1 to
bind thrombin seems to be sufﬁcient to ensure a reduction of
the surface thrombogenicity and blood coagulation. The two
inhibitor-functionalized surfaces demonstrated comparable
antithrombogenic and anticoagulant effects referenced to the
parameters obtained for the reference PTFE TAT
=712±327 g l−1 and PF4=622±428 IU ml−1, respec-
tively. Also, the platelet number in blood did not differ sig-
niﬁcantly between PP-MA-1 and -2, as illustrated in Table
IV. Compared to the value in the blood before incubation,
the decrease of the thrombocyte number after contacting
these amidine-containing materials is only of 6% and 11%
while about 20% of platelets disappeared after incubation in
the presence of PTFE, glass, and PP-MAhyd.
In vivo, the activation of the complement system is
achieved via three different pathways termed classical, lec-
tin, or alternative with three distinct triggers becoming iden-
tical beyond activation of C5. The activation of immunologi-
cal reactions in blood after the contact with biomaterials was
monitored through the detection of the formation of the
complement fragment C5a Fig. 10 which is one of the so-
called anaphylatoxins having potent chemotactic ability for
polymorphonuclear cells and being an activator of mono-
cytes and other leukocytes.51 Also, the formation of terminal
complement complex C5b-9 or membrane attack complex
which is common to the three pathways and capable of in-
serting into biological membranes and producing cell lysis
and death Fig. 11 was detected on the material surfaces.
The complement activation associated with PP-MA-1 and
PP-MA-2 was lower compared to the highly activating glass
materials; however, low C5a production was observed as
well after contact with hydrolyzed polymer ﬁlms. It is known
that negatively charged moieties such as COO− as in
PP-MAhyd promote high-afﬁnity association between the
surface bound C3b and the inhibitory factor H inhibiting the
further formation of complement system convertase. We con-
sider the differences observed depending on the nature of the
inhibitor which was immobilized at the surface as signiﬁ-
cant: lowest activation of immunological reactions in the
blood as well as at the surface of the materials was noticed
TABLE IV. Number of thrombocytes in blood before A and after blood
incubation with samples for 2 h n=5. P=PTFE, G=glass. The results are
shown as mean±standard deviation n=6.
A P G PP-MAhyd PP-MA-1 PP-MA-2
Platelets
109/ l
207 167 165 169 194 184
SD 5 12 16 21 9 11
FIG. 10. Concentration of C5a in blood plasma before A and after blood
incubation with samples for 2 h. Reference materials: P=PTFE and G
=glass. The error bars are standard deviations n=6.
FIG. 11. Relative surface concentration of the terminal complement complex
C5b-9 results referenced to glass material, G=1.0. Reference materials:
P=PTFE and G=glass. The error bars are standard deviations n=4.
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after contact with PP-MA-1 compared to PP-MA-2. As ben-
zamidine molecules in solution are known to inhibit the
complement fragment C1 competitively7 the observed inhi-
bition constant for the p-aminobenzamidine 1 were 1.35 and
0.4 mM for the serine proteases C 1s and C 1r,
respectively,52 we assumed that such compatibility enhance-
ment might be related to an inhibition of the ﬁrst component
of the complement system. It is usually assumed that the
alternative pathway is responsible for the high activation
noted on foreign surfaces.53 However, in vitro results also
supported the role of the ﬁrst component of the classical
pathway C1 in the activation of platelets.54 Our results are in
agreement with the new hypothesis that C1 is playing a role
in the activation caused by foreign materials and that
amidine-type agents could be effective due to their ability to
inhibit subunits of this complement fragment.55
IV. CONCLUSIONS
Our study demonstrates that the use of benzamidine-based
molecules, inhibitors of trypsin-like serine proteases, offer a
promising strategy for blood compatible coatings. Physico-
chemical and biological experiments prove the attachment
and activity of benzamidine-type thrombin inhibitors on top
of macroscopically ﬂat surfaces precoated with reactive ma-
leic anhydride copolymer thin ﬁlms. The inhibitor-decorated
polymer ﬁlms scavenge thrombin even after a preincubation
in the presence of serum albumin with an afﬁnity related to
the antithrombin potency of the molecules in solution. In
vitro hemocompatibility parameters indicate that the immo-
bilization of both synthetic inhibitors signiﬁcantly enhanced
the short term blood compatibility of the coatings. Both in-
hibitor decorated surfaces provided comparable antithrombo-
genic and anticoagulant effects; the higher afﬁnity of the
larger inhibitor to thrombin was not reﬂected by the interac-
tion of the coatings with human whole blood. Thus, even
rather simple inhibitors can be successfully employed to de-
sign hemocompatible materials.
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